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Remission of acute monocytic leukemia, secondary to
treatment with epipodophyllotoxins, in a patient with
t(8;16)(p11;p13) and MYST3–CREBBP fusionThe balanced t(8;16)(p11;p13) is found in less than 1% of
acute myeloid leukemia (AML) patients, usually associated
with specific clinicopathologic findings such as blast differ-
entiation (French–American–British [FAB] subtypes M4/
M5), absence of previous MDS in young individuals of both
sexes, presence of erythrophagocytosis, and poor response
to chemotherapy, with a poor prognosis and mean survival
less than 1 year [1]. This translocation results in the fusion
of the CREBBP gene (alias CBP) located at 16p13.3 with
the MYST3 gene (previously known as RUNXBP2; alias
MOZ) located at 8p11.2 [2,3], which have been suggested to
be targets for topoisomerase II inhibitors and anthracyclines,
respectively. There are, however, very few reported cases of
patients with both this translocation and AML secondary to
treatment with these drugs [3–7].
A 24-year-old man was diagnosed with a mediastinal
seminoma on May 2001. He received four cycles of chemo-
therapy with cisplatin, etoposide, and dexamethasone; the
remaining mediastinal mass was surgically removed. He was
diagnosed with acute monocytic leukemia (FAB subtype
M5b) in November 2002, presumably secondary to treatment
with epipodophyllotoxins. Bone marrow aspirate revealed
infiltration with 92% large blasts weakly positive for myelop-
eroxidase staining and negative for chloroacetate esterase
staining. Immunophenotyping with forward scatter–side
scatter (FS/SS) gating identified two separate populations of
blasts, both of which were CD33, CD15, CD4, CD56,
and CD34. Weak erythrophagocytosis was observed. Cyto-
genetic analysis revealed the karyotype 46,XY,t(8;16)
(p11;p13) in 7% of the metaphases analyzed (Fig. 1A).
Remission was achieved after treatment according to the
PETHEMA protocol, and all metaphases were normal by
December 2002. The patient received a bone marrow trans-
plant and was, at writing, in molecular and cytogenetic
remission.
Fluorescence in situ hybridization (FISH) studies with
bacterial artificial chromosomes (BACs) RPCI-11 461A8
and RPCI-11 95J11 were consistent with a rearrangement
of CBP (Fig. 1B). Reverse transcriptase-polymerase chain
reaction (RT-PCR) [3] confirmed the presence of the in-frame
1128-bp MOZ–CBP fusion transcript (only type I transcript;
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doi:10.1016/j.cancergencyto.2003.12.002Fig. 1C) and also the presence of the CBP–MOZ tran-
script (data not shown). The sequence of the chimeric
transcripts (Fig. 1D) revealed breakpoints similar to those
described previously, fusing exon 16 from MOZ to exon 3
from CBP.
In summary, we describe a t(8;16)(p11;p13) with MOZ-
CBP fusion in a patient with AML 5b secondary to treatment
Fig. 1. (A) Partial G-banding karyotype showing the t(8;16)(p11;p13);
arrows indicate breakpoints. (B) FISH analysis with BACs RPCI-11 461A8
and RPCI-11 95J11. A green signal in der(8) and a red signal in der(16) are
indicative of CBP splitting. A screen-shot from the UCSC Genome Browser
(July 2003 version, http://genome.ucsc.edu) is shown below, displaying the
relative position of the BAC clones used in FISH. (C) RT-PCR amplification
of the chimeric type I MOZ-CBP transcript (1128 bp). Lane M: 1-Kb ladder
Plus molecular weight marker (Invitrogen-Life Technologies, Paisley, UK);
lane 1: patient sample at the moment of diagnosis; lane 2: patient sample
after therapy; lane 3: sample from a healthy subject; lane 4: negative control.
(D) Sequence of the RT-PCR product obtained in (A) showing an in-frame
fusion between MOZ exon 16 and CBP exon 3.
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is usually associated with strong erythrophagocytosis and
CD34/CD56 blasts [7]. This patient, however, dis-
played weak erythrophagocytosis and CD56 blasts, with a
low percentage of cells showing the translocation. Moreover,
RT-PCR detected only type-I (in-frame) fusion transcripts,
but no type II (out-of-frame) transcripts. All these peculiari-
ties could account for the good prognosis of this patient,
who responded well to conventional therapy and is in cytoge-
netic and molecular remission after bone marrow trans-
plantation, in contrast to other published cases.
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